Sandoz Group AG has presented its strategy for the next ten years, which aims to further position the company as a leading provider of affordable medicines.
affordable pharmaceuticals. The plan is to drive growth in the core generics business through targeted product launches, particularly in the area of oral dosage forms and injectables,
and injectables.
In addition, the presence in the biosimilars market is to be further expanded with an extended portfolio and a strong pipeline.
A particular focus is on exploiting the market opportunities arising from the imminent expiry of patents for drugs worth over USD 600 billion worldwide.
Sandoz is pursuing the goal of increasing patient access to
access to affordable medicines over the next ten years and plans to focus on emerging segments such as the GLP-1 market.
GLP-1 market.